Article
[New agents for the treatment of hepatitis C].
Enfermedades infecciosas y microbiologia clinica - 1 Mar 2012
Buti Maria, Homs Maria
Abstract excerpt
The current treatment of Chronic Hepatitis C (CHC) is based on the combination of peginterferon alpha 2a or 2b and ribavirin. This treatment achieves Sustained Virological Response (SVR) rates in more than 50% of the patients. The SVR rates are higher in genotype 2 and 3 patients than in genotype 1, which account for more than 50%. For this reason, the development of new drugs is needed. The knowledge of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
